Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity.

Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity.

Evaluation of: Yan M, Callahan CA, Beyer JC et al.: Chronic DLL4 blockade induces vascular neoplasms. Nature 463, E6-E7 (2010). Delta-like ligand 4 (DLL4) is a Notch ligand that is critical in the formation of a functional vascular network in tumors. Blockade of DLL4-mediated Notch signaling strikin...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Li, J, Jubb, A, Harris, A
Natura:	Journal article
Lingua:	English
Pubblicazione:	2010

Documenti analoghi

Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer.
di: Jubb, A, et al.
Pubblicazione: (2009)

Dll4/Notch Signaling Pathway and Tumor Angiogenesis
di: Xinyu DING, et al.
Pubblicazione: (2009-11-01)

DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
di: Li, J, et al.
Pubblicazione: (2011)

DLL4-Notch Signaling Mediates Tumor Resistance to Anti-VEGF Therapy In Vivo
di: Li, J, et al.
Pubblicazione: (2011)

Expression of DLL4 and VEGF in Lung Adenocarcinoma and their Relationship with Angiogenesis in Tumor
di: Xiaoping LI, et al.
Pubblicazione: (2009-02-01)

Context-Dependent Functional Divergence of the Notch Ligands DLL1 and DLL4 In Vivo.
di: Kristina Preuße, et al.
Pubblicazione: (2015-06-01)

Down regulating Delta-4 (DLL4) using RNA interference - a potential future treatment for bladder cancer
di: Patel, N, et al.
Pubblicazione: (2005)

Distinct expression patterns of Notch ligands, Dll1 and Dll4, in normal and inflamed mice intestine
di: Hiromichi Shimizu, et al.
Pubblicazione: (2014-05-01)

Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
di: Sainson, R, et al.
Pubblicazione: (2007)

Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis
di: Liu Ren, et al.
Pubblicazione: (2010-11-01)

Parit-parit [dll.]

Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo
di: Geffers, I, et al.
Pubblicazione: (2007)

Polyethylenimine Triggers Dll4 Degradation to Regulate Angiogenesis In Vitro
di: Binghua Cheng, et al.
Pubblicazione: (2024-02-01)

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
di: Hussein Al-Sudani, et al.
Pubblicazione: (2023-07-01)

DLL3: an emerging target in small cell lung cancer
di: Dwight H. Owen, et al.
Pubblicazione: (2019-06-01)

The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro
di: Lena Tveriakhina, et al.
Pubblicazione: (2018-10-01)

Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells.
di: Harrington, L, et al.
Pubblicazione: (2008)

Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.
di: Carla Real, et al.
Pubblicazione: (2011-01-01)

The potential value of Notch1 and DLL1 in the diagnosis and prognosis of patients with active TB
di: Jinling Xie, et al.
Pubblicazione: (2023-03-01)

The role of DLL4-NOTCH signalling in endothelial cell metabolism
di: Harjes, U
Pubblicazione: (2014)

RHOQ is induced by DLL4 and regulates angiogenesis by determining the intracellular route of the Notch intracellular domain
di: Bridges, E, et al.
Pubblicazione: (2020)

The Role of Dll4/Notch Signaling in Normal and Pathological Ocular Angiogenesis: Dll4 Controls Blood Vessel Sprouting and Vessel Remodeling in Normal and Pathological Conditions
di: Ivan Lobov, et al.
Pubblicazione: (2018-01-01)

Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
di: Trace M. Jones, et al.
Pubblicazione: (2019-11-01)

The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis.
di: Bridge, G, et al.
Pubblicazione: (2012)

The Regulation of para-Nitrophenol Degradation in Pseudomonas putida DLL-E4.
di: Qiongzhen Chen, et al.
Pubblicazione: (2016-01-01)

1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models
di: Keegan Cooke, et al.
Pubblicazione: (2023-11-01)

Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues.
di: Martinez, J, et al.
Pubblicazione: (2009)

MItra Bestari, Petunjuk penulisan, dll
di: DPPM Editor
Pubblicazione: (2016-03-01)

Petunjuk penulisan, MItra Bestari, dll
di: DPPM Editor
Pubblicazione: (2016-03-01)

MPDZ promotes DLL4-induced Notch signaling during angiogenesis
di: Fabian Tetzlaff, et al.
Pubblicazione: (2018-04-01)

Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer
di: Yoshitaka Isobe, et al.
Pubblicazione: (2020-02-01)

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
di: Bilal H. Lashari, et al.
Pubblicazione: (2018-09-01)

Preclinical models of radiation-induced cardiac toxicity: Potential mechanisms and biomarkers
di: Alexandra D. Dreyfuss, et al.
Pubblicazione: (2022-10-01)

Expressions and Prognostic Values of Notch3 and DLL4 in Human Breast Cancer
di: Lin Wang, et al.
Pubblicazione: (2023-02-01)

Jambatan Pulau Pinang : himpunan sajak, cerpen, dll /
di: 408021 Zainal Abidin S. A. M. Jamalullail
Pubblicazione: (1990)

Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis
di: Nan W. Hultgren, et al.
Pubblicazione: (2020-10-01)

630 PD-L1/CD47 tumor directed B-BodyTM bispecific antibodies demonstrating significant anti-tumor activity with no toxicity in preclinical models
di: Peter Lamb, et al.
Pubblicazione: (2020-11-01)

Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic Steatohepatitis in Ldlr-/- Mice.
di: Mike L J Jeurissen, et al.
Pubblicazione: (2016-01-01)

Analysis of a DS-CDMA receiver DLL architecture
di: Moss, J, et al.
Pubblicazione: (1996)

Human iPSC-derived preclinical models to identify toxicity of tumor-specific T cells with clinical potential
di: Rosa A. van Amerongen, et al.
Pubblicazione: (2023-03-01)